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Background
Mineralocorticoid-receptor antagonists improve the prognosis for patients with 
heart failure and a reduced left ventricular ejection fraction. We evaluated the ef-
fects of spironolactone in patients with heart failure and a preserved left ventricular 
ejection fraction.
Methods
In this randomized, double-blind trial, we assigned 3445 patients with symptomatic 
heart failure and a left ventricular ejection fraction of 45% or more to receive either 
spironolactone (15 to 45 mg daily) or placebo. The primary outcome was a composite 
of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for 
the management of heart failure.
Results
With a mean follow-up of 3.3 years, the primary outcome occurred in 320 of 
1722 patients in the spironolactone group (18.6%) and 351 of 1723 patients in 
the placebo group (20.4%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.77 
to 1.04; P = 0.14). Of the components of the primary outcome, only hospitalization 
for heart failure had a significantly lower incidence in the spironolactone group 
than in the placebo group (206 patients [12.0%] vs. 245 patients [14.2%]; hazard 
ratio, 0.83; 95% CI, 0.69 to 0.99, P = 0.04). Neither total deaths nor hospitalizations 
for any reason were significantly reduced by spironolactone. Treatment with spir-
on olactone was associated with increased serum creatinine levels and a doubling of 
the rate of hyperkalemia (18.7%, vs. 9.1% in the placebo group) but reduced hypo-
kalemia. With frequent monitoring, there were no significant differences in the 
incidence of serious adverse events, a serum creatinine level of 3.0 mg per deciliter 
(265 μmol per liter) or higher, or dialysis.
Conclusions
In patients with heart failure and a preserved ejection fraction, treatment with spir-
onolactone did not significantly reduce the incidence of the primary composite 
outcome of death from cardiovascular causes, aborted cardiac arrest, or hospital-
ization for the management of heart failure. (Funded by the National Heart, Lung, 
and Blood Institute; TOPCAT ClinicalTrials.gov number, NCT00094302.)
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Many patients with heart failure have a normal or near-normal left ven-tricular ejection fraction.1-4 Such patients 
share common signs and symptoms, as well as 
an impaired quality of life and a poor prognosis, 
with patients who have heart failure and a re-
duced ejection fraction.5-8 However, the benefit 
of most medical therapies for heart failure is lim-
ited to those with a reduced ejection fraction, 
generally 40% or less.1,2,9 The lack of favorable 
evidence from clinical-outcome trials involving 
patients with heart failure and a preserved left 
ventricular ejection fraction is reflected in cur-
rent guidelines, which offer no specific recom-
mendations for the management of heart failure 
in such patients except for attention to coexisting 
conditions.10-12
Among patients with heart failure and a re-
duced ejection fraction and those with myocar-
dial infarction complicated by heart failure and 
left ventricular dysfunction, mineralocorticoid-
receptor antagonists have been shown to be 
 effective in reducing overall mortality and hos-
pitalizations for heart failure.13-15 In small mecha-
nistic studies involving patients with heart failure 
and preserved left ventricular function, mineralo-
corticoid-receptor antagonists improved measures 
of diastolic function.16,17 However, their effect on 
clinical outcomes in such patients has not been 
rigorously tested. We therefore initiated the Treat-
ment of Preserved Cardiac Function Heart Failure 
with an Aldosterone Antagonist (TOPCAT) trial to 
determine whether treatment with spironolactone 
would improve clinical outcomes in patients with 
symptomatic heart failure and a relatively pre-
served ejection fraction.18,19
Me thods
Study Design and Oversight
We designed a phase 3, multicenter, internation-
al, randomized, double-blind, placebo-controlled 
trial. The trial was sponsored by the National 
Heart, Lung, and Blood Institute. The executive 
and steering committees designed the trial and 
oversaw its conduct; the ethics committee at 
each study site approved the trial design. Data 
were collected and managed electronically by the 
New England Research Institutes Clinical Trial 
Coordinating Center, which also coordinated site 
monitoring and analyzed the trial results (with 
independent verification at Brigham and Women’s 
Hospital). The first draft of the manuscript was 
written by the first three authors and the last 
author. All the authors edited and approved the 
manuscript and assume full responsibility for the 
accuracy and completeness of the data and for 
the fidelity of this report to the study protocol, 
which is available with the full text of this article 
at NEJM.org. Further details concerning study 
design and oversight are provided in the Supple-
mentary Appendix, available at NEJM.org.
Study Patients
Patients 50 years of age or older were eligible if 
they provided written informed consent and had 
at least one sign and at least one symptom of heart 
failure on a prespecified list of clinically defined 
signs and symptoms, a left ventricular ejection 
fraction of 45% or more as measured at the local 
site by means of echocardiography or radionuclide 
ventriculography, controlled systolic blood pres-
sure (defined as a target systolic blood pressure of 
<140 mm Hg or ≤160 mm Hg if the patient was 
taking three or more medications to control 
blood pressure), and a serum potassium level of 
less than 5.0 mmol per liter. In addition, eligible 
patients had a history of hospitalization within 
the previous 12 months, with management of 
heart failure a major component of the care pro-
vided (not adjudicated by the clinical-events adju-
dication committee), or an elevated natriuretic pep-
tide level within 60 days before randomization 
(a brain natriuretic peptide [BNP] level ≥100 pg 
per milli liter or an N-terminal pro-BNP [NT-
proBNP] level ≥360 pg per milliliter). Trial ran-
domization was stratified according to whether 
patients were enrolled on the basis of the first 
criterion (designated the hospitalization stratum) 
or the second criterion (designated the BNP stra-
tum). The second criterion was considered only 
for those who did not meet the first criterion.
Exclusion criteria were severe systemic illness 
with a life expectancy of less than 3 years, severe 
renal dysfunction (an estimated glomerular filtra-
tion rate [GFR] of <30 ml per minute per 1.73 m2 
of body-surface area or a serum creatinine level 
that was ≥2.5 mg per deciliter [221 μmol per liter]), 
and specific coexisting conditions, medications, or 
acute events.19 A full list of inclusion and exclusion 
criteria is provided in the Supplementary Appendix.
Randomization and Study Drugs
Eligible participants were randomly assigned to 
receive either spironolactone or placebo in a 
1:1 ratio with the use of permuted blocks. As 
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noted above, randomization was stratified ac-
cording to whether the patient met the criterion 
for previous hospitalization or BNP elevation. 
Study drugs were purchased as 15-mg tablets of 
spironolactone or matching placebo (United Re-
search Laboratories and Mutual Pharmaceutical). 
Study drugs were initially administered at a dose of 
15 mg once daily, which was increased to a maxi-
mum of 45 mg daily during the first 4 months after 
randomization. Subsequent dose adjustments were 
made as required. Measurement of potassium and 
creatinine levels was required within 1 week after 
a change in the study-drug dose and at each sched-
uled study visit (Fig. S1 in the Supplementary Ap-
pendix). Study patients continued to receive other 
treatments for heart failure and co existing illnesses 
throughout the trial. Further details concerning 
dose adjustments and follow-up assessments are 
provided in the Supplementary Appendix.
Outcomes
The primary outcome was a composite of death 
from cardiovascular causes, aborted cardiac ar-
rest, or hospitalization for the management of 
heart failure. All occurrences of the individual 
components of the primary outcome, as well as 
myocardial infarctions and strokes, were adjudi-
cated by a clinical end-point committee at 
Brigham and Women’s Hospital according to 
prespecified criteria; members of the committee 
were unaware of the study-drug assignments.18 
Other outcomes included death from any cause, 
hospitalization for any cause, hyperkalemia (po-
tassium level, ≥5.5 mmol per liter), hypokalemia 
(potassium level, <3.5 mmol per liter), an elevated 
serum creatinine level (≥2 times the baseline 
value and above the upper limit of the normal 
range), and a serum creatinine level of 3.0 mg per 
deciliter (265 μmol per liter) or higher. A detailed 
summary of the criteria defining the individual 
trial-outcome measures reported here is provided 
in the Supplementary Appendix.
Statistical Analysis
The trial was designed to have 80% power to de-
tect a 20% relative reduction from a 3-year primary 
outcome rate of 17.4%, with an overall type I error 
of 0.05 (two-sided test). After accounting for in-
terim monitoring (see the Methods section in the 
Supplementary Appendix), we calculated that 
data on 551 participants with primary outcomes 
confirmed by the clinical end-point committee 
would be needed to achieve 80% power, and data 
on 630 participants with primary outcomes 
would be needed to achieve 85% power. The tar-
get enrollment was 3515 patients.18
All randomly assigned participants were in-
cluded in all analyses according to the intention-
to-treat principle. For prespecified comparisons of 
multiple hospitalizations, the planned Poisson re-
gression model was replaced with a negative bino-
mial model to allow for correlated events. All other 
analyses were prespecified unless stated other-
wise. Participants were followed for clinical and 
laboratory outcomes through their last semian-
nual visit, between January 1, 2013, and June 30, 
2013, or until the last contact. For those who 
withdrew or were lost to follow-up, attempts were 
made to obtain vital status as of the last potential 
study visit.
The prespecified primary analysis was a time-
to-event analysis with the use of the unadjusted 
log-rank test. Cox proportional-hazards models 
were used to obtain unadjusted and covariate-
adjusted hazard ratios. Data on participants who 
did not have a primary-outcome event were cen-
sored at the date of last available follow-up in-
formation for clinical events. The same approach 
was used for other time-to-event outcomes. For 
death from any cause, data were censored on the 
last date that the participant was known to be 
alive, which may have been later than the last 
clinical follow-up. Incidence rates per 100 person-
years were also calculated.
Comparisons of recurrent hospitalizations for 
heart failure and hospitalizations for any cause 
were performed with the use of negative binomial 
regression. Longitudinal linear regression meth-
ods, without adjustment, were used for labora-
tory and blood-pressure measurements. A total 
of 22 prespecified subgroup analyses were con-
ducted for the primary outcome. To assess the 
homogeneity of study-drug effects across sub-
groups, we used a Cox proportional-hazards 
model, including study group, the subgroup 
variable, and their interaction.20 No adjustments 
were made for multiple comparisons.
R esult s
Study Patients and Follow-up
From August 10, 2006, to January 31, 2012, a total 
of 3445 participants at 233 sites in 6 countries 
(1151 participants in the United States, 326 in 
Canada, 167 in Brazil, 123 in Argentina, 1066 in 
Russia, and 612 in Georgia) were randomly as-
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Table 1. Selected Baseline Characteristics of the Study Patients.*
Characteristic
Spironolactone  
(N = 1722)
Placebo  
(N = 1723)
Age — yr
Median 68.7 68.7
Interquartile range 61.0–76.4 60.7–75.5
Age ≥75 yr — no. (%) 495 (28.7) 453 (26.3)
Female sex — no. (%) 888 (51.6) 887 (51.5)
White race — no. (%)† 1525 (88.6) 1537 (89.2)
Left ventricular ejection fraction — %
Median 56 56
Interquartile range 51–61 51–62
NYHA functional classification — no. (%)
I 56 (3.3) 53 (3.1)
II 1090 (63.3) 1104 (64.1)
III 568 (33.0) 553 (32.1)
IV 7 (0.4) 8 (0.5)
Missing data 1 (<0.1) 5 (0.3)
Eligibility stratum
Hospitalization in previous year with management of heart failure  
as major component — no. (%)
1232 (71.5) 1232 (71.5)
Elevated natriuretic peptides in previous 60 days — no. (%)‡ 490 (28.5) 491 (28.5)
BNP — pg/ml
Median 236 235
Interquartile range 149–414 141–410
NT-proBNP — pg/ml
Median§ 887 1017
Interquartile range 537–1634 627–2258
Current smoker — no. (%) 176 (10.2) 184 (10.7)
Blood pressure — mm Hg
Systolic
Median 130 130
Interquartile range 120–139 120–140
Diastolic
Median 80 80
Interquartile range 70–80 70–80
Heart rate — beats/min
Median 68 68
Interquartile range 62–76 62–76
Body-mass index¶
Median 31 31
Interquartile range 27–36 27–36
Serum potassium — mmol/liter
Median 4.3 4.3
Interquartile range 4.0–4.6 4.0–4.6
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signed to receive spirono lactone (1722 partici-
pants) or placebo (1723). A total of 2464 par-
ticipants (71.5%) were enrolled in the hospital-
ization stratum, and 981 (28.5%) were enrolled 
in the BNP stratum (Fig. S2 in the Supplemen-
tary Appendix). The study groups were balanced 
with respect to baseline characteristics (Table 1, 
and Table S1 in the Sup plementary Appendix).
The mean follow-up interval was 3.3 years in 
each study group. A total of 311 participants — 
160 in the spironolactone group (9.3%) and 151 in 
the placebo group (8.8%) — discon tinued study 
participation before the last expected study visit 
for reasons other than death (Fig. S2 in the 
Supplementary Appendix). Vital status as of the 
last expected study visit was unknown for 67 par-
ticipants in the spironolactone group (3.9%) and 
65 participants in the placebo group (3.8%).
Study Drug Administration
The distribution of daily study-drug doses at 
8 months after randomization is shown accord-
ing to study group in Table S2 in the Supplemen-
tary Appendix. The mean dose at 8 months was 
25.0 mg per day in the spironolactone group and 
27.7 mg per day in the placebo group. There were 
590 participants in the spironolactone group 
(34.3%) and 541 in the placebo group (31.4%) 
who permanently discontinued the study drug 
while continuing to be followed for study out-
comes. Tables S3A and S3B in the Supplementary 
Appendix show the timing of and reasons for 
early discontinuation of the study drug.
Primary-Outcome and Component Events
A total of 671 participants had at least one con-
firmed primary-outcome event: 320 in the spiro-
nolactone group (18.6%) and 351 in the placebo 
group (20.4%). These numbers correspond to in-
cidence rates of 5.9 events per 100 person-years 
and 6.6 events per 100 person-years, respectively 
(P = 0.14 by the log-rank test). The unadjusted 
hazard ratio was 0.89 (95% confidence interval 
[CI], 0.77 to 1.04) (Table 2 and Fig. 1). The inci-
Table 1. (Continued.)
Characteristic
Spironolactone  
(N = 1722)
Placebo  
(N = 1723)
Serum creatinine — mg/dl‖
Median 1.0 1.1
Interquartile range 0.9–1.2 0.9–1.2
Estimated GFR — ml/min/1.73 m2
Median 65.3 65.5
Interquartile range 53.9–79.2 53.5–79.1
Hemoglobin — g/dl
Median 13.2 13.3
Interquartile range 12.1–14.4 12.2–14.5
Region of enrollment — no. (%)
Americas** 886 (51.5) 881 (51.1)
Russia and Georgia 836 (48.5) 842 (48.9)
* There were no significant differences between the two groups except as indicated. GFR denotes glomerular filtration 
rate, and NYHA New York Heart Association.
† Race was determined according to self-report.
‡ Patients in this stratum were enrolled on the basis of elevated levels of brain natriuretic peptide (BNP) or N-terminal 
pro-BNP (NT-proBNP), measured within 60 days before randomization. The study-qualifying BNP or NT-proBNP values 
were reported in 868 of 981 patients enrolled in this stratum (88.5%); values were not collected for 113 patients 
(11.5%) who were enrolled before a change to the enrollment form was implemented in August 2007. BNP values 
were reported for 229 patients in the spironolactone group and 239 patients in the placebo group; NT-proBNP values were 
reported for 203 patients in the spironolactone group and 197 patients in the placebo group.
§ P = 0.04.
¶ The body-mass index was calculated as the weight in kilograms divided by the square of the height in meters.
‖ To convert values for creatinine to micromoles per liter, multiply by 88.4.
** The Americas included the United States, Canada, Argentina, and Brazil.
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dence rates and the adjusted models are shown 
in Table S4 in the Supplementary Appendix.
Death from cardiovascular causes occurred in 
160 patients in the spironolactone group (9.3%) 
and 176 patients in the placebo group (10.2%), 
with a hazard ratio of 0.90 (95% CI, 0.73 to 1.12; 
P = 0.35 by the log-rank test) (Fig. 2A). Aborted 
cardiac arrest occurred in 3 patients in the spir-
onolactone group (0.2%) and 5 patients in the 
placebo group (0.3%) (P = 0.48 by the log-rank 
test). Hospitalization for heart failure occurred in 
206 patients in the spironolactone group (12.0%) 
and 245 patients in the placebo group (14.2%), 
with a hazard ratio of 0.83 (95% CI, 0.69 to 0.99; 
P = 0.04 by the log-rank test) (Fig. 2B). Approxi-
mately two thirds of first primary-outcome events 
were hospitalizations for heart failure. In an 
analysis of total hospitalizations (including re-
peat hospitalizations) for heart failure over the 
entire study period, the frequency was lower in 
the spironolactone group than in the placebo 
group (394 vs. 475 hospitalizations; 6.8 vs. 8.3 
per 100 person-years; P = 0.03).
The results of analyses of the primary out-
come in 22 prespecified subgroups are shown in 
Figure S3 in the Supplementary Appendix. Study-
drug effects differed significantly only according 
to randomization stratum (P = 0.01 for interac-
Table 2. Incidence Rates of the Primary Composite Outcome, Its Components, and Additional Secondary Outcomes.*
Outcome
Spironolactone  
(N = 1722)
Placebo  
(N = 1723)
Hazard Ratio with 
Spironolactone  
(95% CI)† P Value
Participants  
with Event
Incidence  
Rate
Participants  
with Event
Incidence  
Rate
no. (%) no./100 person-yr no. (%) no./100 person-yr
Primary outcome 320 (18.6) 5.9 351 (20.4) 6.6 0.89 (0.77–1.04) 0.14
Components of the primary 
 outcome
Death from cardiovascular 
causes
160 (9.3) 2.8 176 (10.2) 3.1 0.90 (0.73–1.12) 0.35
Aborted cardiac arrest 3 (0.2) 0.05 5 (0.3) 0.09 0.60 (0.14–2.50) 0.48
Hospitalization for heart failure 206 (12.0) 3.8 245 (14.2) 4.6 0.83 (0.69–0.99) 0.04
Additional secondary outcomes
Death from any cause 252 (14.6) 4.2 274 (15.9) 4.6 0.91 (0.77–1.08) 0.29
Hospitalization for any reason 766 (44.5) 18.8 792 (46.0) 20.0 0.94 (0.85–1.04) 0.25
Myocardial infarction 65 (3.8) 1.2 64 (3.7) 1.1 1.00 (0.71–1.42) 0.98
Stroke 57 (3.3) 1.0 60 (3.5) 1.1 0.94 (0.65–1.35) 0.73
* Some participants had more than one component of the primary outcome and are included once for the primary outcome and once for 
each component they had.
† Shown are unadjusted hazard ratios calculated with the use of Cox proportional-hazards models.
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Figure 1. Kaplan–Meier Plot of Time to the First Confirmed Primary-Outcome 
Event.
The primary outcome was a composite of death from cardiovascular causes, 
aborted cardiac arrest, or hospitalization for the management of heart failure. 
The inset shows the same data on an expanded y axis.
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tion). In the hospitalization stratum, spiro no lac-
tone had no effect on the time to the composite 
outcome (hazard ratio, 1.01; 95% CI, 0.84 to 1.21; 
P = 0.92), whereas in the BNP stratum, spirono-
lactone showed a benefit (hazard ratio, 0.65; 
95% CI, 0.49 to 0.87; P = 0.003) (see Table S5A in 
the Supplementary Appendix for the primary 
outcome and its components according to ran-
domization stratum). As compared with patients 
in the hospitalization stratum, patients in the 
BNP stratum were older; were less likely to be 
current smokers; had higher baseline creatinine 
levels, lower potassium levels, and lower esti-
mated GFRs; and were less likely to be enrolled 
at sites in Russia or Georgia (Table S5B in the 
Supplementary Appendix).
Post hoc analysis indicated marked regional 
differences in event rates (Table S6 in the Supple-
mentary Appendix). In the Americas (the United 
States, Canada, Brazil, and Argentina), the pri-
mary outcome occurred in 242 patients in the 
spironolactone group (27.3%) and 280 patients 
in the placebo group (31.8%). In Russia and 
Georgia, the primary outcome occurred in 78 
patients in the spironolactone group (9.3%) and 
71 patients in the placebo group (8.4%). How-
ever, the prespecified test for interaction be-
tween region and study group was not signifi-
cant (P = 0.12) (Fig. S3 in the Supplementary 
Appendix).
Secondary Outcomes
There were no significant differences between 
study groups in time to death from any cause or 
first hospitalization for any reason (Table 2 and 
Fig. 3, and Fig. S4 in the Supplementary Appendix). 
Causes of death were generally similar between 
the two groups (Table S7 in the Supplementary 
Appendix). The frequency of hospitalization for 
any reason (including recurrent hospitalization) 
did not differ significantly according to study 
group (36.8 hospitalizations per 100 person-
years in the spironolactone group and 36.3 per 
100 person-years in the placebo group, P = 0.71). 
There were no significant differences in rates of 
myocardial infarction or stroke between the 
groups (Table 2).
Adverse Events
There were 2395 serious adverse events in the 
spironolactone group and 2387 in the placebo 
group (41.6 per 100 person-years and 41.8 per 
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Figure 2. Kaplan–Meier Plots of Two Components of the Primary  
Outcome.
Panel A shows the time to confirmed death from cardiovascular causes, 
and Panel B the time to the first confirmed hospitalization for heart failure. 
The insets show the same data on an expanded y axis.
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100 person-years, respectively). The spironolac-
tone group had a higher rate of hyperkalemia 
(18.7%, vs. 9.1% in the placebo group) and a lower 
rate of hypokalemia (16.2% vs. 22.9%). The spir-
onolactone group was more likely to have a dou-
bling of the serum creatinine level to a value 
above the upper limit of the normal range 
(10.2% vs. 7.0%). However, there were no sig-
nificant between-group differences in the pro-
portion of patients with a serum creatinine level 
of 3.0 mg per deciliter or higher or who required 
dialysis. Systolic blood pressure at postbaseline 
visits was significantly lower in the spironolac-
tone group. In addition, discontinuation of the 
study drug due to breast tenderness or gyneco-
mastia was significantly more frequent in the 
spironolactone group. A more detailed descrip-
tion of the adverse events is provided in the 
Supplementary Appendix, including Table S8.
Discussion
The TOPCAT trial was adequately powered for 
its composite primary outcome of death from 
cardiovascular causes, aborted cardiac arrest, 
or hospitalization for heart failure. We found 
that adding spironolactone to existing therapy 
in patients with heart failure and a preserved 
ejection fraction did not significantly reduce the 
incidence of the primary outcome.
Neither the time to first hospitalization for 
any reason nor the time to death from any cause 
was significantly altered by random assignment 
to spironolactone. These two inclusive outcome 
measures are important for assessing overall 
risk versus benefit but were not anticipated to 
be significantly reduced by a therapy address-
ing only one aspect of the broad range of coex-
isting conditions in this patient population. 
The incidence rates of death from any cause 
and of hospitalization for heart failure in our 
placebo group (4.6 events per 100 person-years 
for each outcome) are similar to rates observed 
in other major trials involving patients with 
heart failure and a preserved ejection frac-
tion21-25 and are considerably higher than those 
in trials involving patients with hypertension,26 
diabetes,27 or stable coronary artery disease.28,29
In the context of a neutral primary finding, 
all other secondary analyses should be consid-
ered as provisional. However, the individual 
components of any composite primary end 
point are always important in interpreting the 
overall trial result. Death from cardiovascular 
causes occurred in approximately 10% of pa-
tients and did not differ significantly between 
the study groups. Survival of a documented car-
diac arrest occurred in only eight patients. Hos-
pitalization for heart failure was the most com-
mon component of the primary outcome, and 
the rate of this outcome was reduced in the 
spironolactone group, a finding that was rein-
forced by the results of a prespecified analysis 
of cumulative hospitalizations for heart failure.
Of the 22 prespecified subgroups, only the 
eligibility stratum was associated with a sig-
nificant treatment interaction. Spironolactone 
significantly reduced the rate of the primary 
outcome among patients enrolled on the basis 
of an elevated natriuretic peptide level but not 
among those enrolled on the basis of a previous 
hospitalization for heart failure. This could be 
a chance finding, given the multiple analyses. 
However, we noted multiple differences in the 
baseline characteristics of patients according to 
stratum. In the placebo group in the TOPCAT 
trial, there was an unexpectedly lower risk30,31 
of the primary outcome among those who had 
been hospitalized previously than among those 
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Figure 3. Kaplan–Meier Plot of Time to Death from Any Cause.
The inset shows the same data on an expanded y axis.
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who had not (Table S5A in the Supplementary 
Appendix). In addition, the great majority of 
patients from Russia and Georgia were enrolled 
in the hospitalization stratum, whereas patients 
from the Americas were more evenly balanced 
between the two strata (Table S5B in the Supple-
mentary Appendix).
These unanticipated observations led to addi-
tional, exploratory post hoc analyses. We observed 
a marked regional variation in event rates, with 
patients in the placebo group who were en-
rolled in Russia or Georgia having a much 
lower likelihood of a primary-outcome event 
than those enrolled in the Americas (Table S6 in 
the Supplementary Appendix). This discrepancy 
in event rates with placebo was unexpected and 
is unexplained. However, it may reflect regional 
heterogeneity of coexisting conditions and prac-
tice patterns,32-35 including differential use of 
hospitalization, as well as the clinical challenges 
in diagnosing heart failure with a preserved 
ejection fraction.36 The discrepancy in event rates 
with placebo may have contributed to the ob-
served treatment benefit in the Americas but 
not in Russia or Georgia (where low event rates 
would be difficult to reduce further) and the 
observed treatment benefit among patients en-
rolled in the BNP stratum but not among those 
enrolled in the hospitalization stratum (because 
most of the patients enrolled in Russia and 
Georgia were in the hospitalization stratum).
The achieved dose of spironolactone in the 
TOPCAT trial was similar to the mean dose in 
the Randomized Aldactone Evaluation Study,14 
and dose adjustments were limited by elevations 
in serum creatinine and potassium levels. Ap-
proximately one third of participants discontin-
ued the study drug for these and other reasons, 
which is an additional important limitation of 
our trial. There was a significant increase in 
hyperkalemia and an increase in serum creatinine 
levels with spironolactone, findings that under-
score the importance of monitoring if spirono-
lactone is used in patients with heart failure and 
a preserved ejection fraction.
In conclusion, we compared spironolactone 
with placebo for the treatment of heart failure 
with a preserved ejection fraction. Spironolac-
tone did not significantly reduce the composite 
primary end point of death from cardiovascular 
causes, aborted cardiac arrest, or hospitaliza-
tion for heart failure.
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